TNFRSF17 and Miyoshi myopathy: Preclinical studies of a humanized anti-BCMA antibody-drug conjugate J6M0-mcMMAF (known clinically as GSK2857916) identified two mechanisms of cytotoxicity (recruitment of macrophages and ADCC) in response to administration in mouse models of MM [147].